Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

Background Proteinuria monitoring is required in patients receiving lenvatinib, however, current methodology involves burdensome overnight urine collection. Methods To determine whether the simpler urine protein:creatinine ratio (UPCR) calculated from spot urine samples could be accurately used for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2019-07, Vol.121 (3), p.218-221
Hauptverfasser:	Evans, Thomas R. Jeffry, Kudo, Masatoshi, Finn, Richard S., Han, Kwang-Hyub, Cheng, Ann-Lii, Ikeda, Masafumi, Kraljevic, Silvija, Ren, Min, Dutcus, Corina E., Piscaglia, Fabio, Sung, Max W.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67 692/4028/67 Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - urine Creatinine Creatinine - urine Drug Resistance Epidemiology Hepatocellular carcinoma Humans Inhibitor drugs Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - urine Molecular Medicine Oncology Patients Phenylurea Compounds - therapeutic use Proteins Proteinuria Proteinuria - therapy Quinolines - therapeutic use Regression analysis Sorafenib - therapeutic use Statistical analysis Targeted cancer therapy Urine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!